主管单位:中华人民共和国
国家卫生健康委员会
主办单位:中国医师协会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Yang Junxia Fang Zhe
英文单位:Department of Cardiology Yanbian University Hospital Yanji 133000 China
关键词:经导管主动脉瓣置换术;主动脉瓣狭窄;临床应用;远期效果
英文关键词:Transcatheteraorticvalvereplacement;Aorticstenosis;Clinicalimplementation;Long-termeffects
我国心脏瓣膜病通常是由风湿性心脏病引起,然而,随着公共卫生条件的日益改善,风湿性疾病的患病率已大幅下降,瓣膜疾病现在大多由退行性病变引起,如退行性主动脉瓣狭窄。通过胸骨切开术进行开放式外科瓣膜置换虽然提供了良好的临床预后,但该治疗方法仍存在较高的手术风险。经导管主动脉瓣置换术(TAVR)是治疗严重主动脉瓣狭窄的一种微创方法,由于其优点众多,成为了中高危瓣膜疾病患者的首选治疗方法。这项新技术目前受到了心血管领域高度关注,引领了微创心脏经皮介入术的新革命。本文对TAVR的技术简介、临床应用及远期效果进行综述。
Valvular heart disease in China is usually caused by rheumatic heart disease. However, with increasingly improved public health conditions, the prevalence of rheumatic diseases has decreased substantially, and valvular diseases are now mostly caused by degenerative lesions, such as degenerative aortic stenosis. Although open surgical valve replacement via sternotomy provides a good clinical prognosis, this treatment method still carries a high surgical risk. Transcatheter aortic valve replacement (TAVR) is a minimally invasive method for the treatment of severe aortic stenosis. Because of its many advantages, it has become the first choice for patients with middle- to high-risk valve disease. At present, this new technology has attracted great attention in the cardiovascular field, leading to a new revolution in minimally invasive percutaneous cardiac intervention. This article reviews the technical introduction, clinical application and long-term effects of TAVR.
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。